Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma.
Acta Obstet Gynecol Scand
; 73(8): 658-62, 1994 Sep.
Article
en En
| MEDLINE
| ID: mdl-7941993
The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CP) or cyclophosphamide, doxorubicin and cisplatinum (CAP). Patients with serum CA-125 values below the normal value of 35 U/ml after two courses had a significantly longer median survival (p < 0.0001) and longer disease-free survival (p = 0.007) than did those patients whose CA-125 levels dropped to normal after the third or a later course of chemotherapy. A response in CA-125 levels after the first two courses of chemotherapy may indicate which patients should continue with the current chemotherapy regimen and which patients should be offered salvage therapy.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Adenocarcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Antígeno Ca-125
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Acta Obstet Gynecol Scand
Año:
1994
Tipo del documento:
Article
País de afiliación:
Israel
Pais de publicación:
Estados Unidos